Solid Biosciences Inc. Auditor
The independent registered public accounting firm that signed the audit report in each annual report on Form 10-K, newest first. PCAOB firm ID and the internal-control attestation are as tagged on the cover from fiscal 2021; earlier rows come from the signed report text.
- 2026-03-19: Fiscal year end 2025-12-31; Auditor PricewaterhouseCoopers LLP; PCAOB firm ID 238; Location Boston, Massachusetts.
- 2025-03-06: Fiscal year end 2024-12-31; Auditor PricewaterhouseCoopers LLP; PCAOB firm ID 238; Location Boston, Massachusetts.
- 2024-03-13: Fiscal year end 2023-12-31; Auditor PricewaterhouseCoopers LLP; PCAOB firm ID 238; Location Boston, Massachusetts.
- 2023-03-23: Fiscal year end 2022-12-31; Auditor PricewaterhouseCoopers LLP; PCAOB firm ID 238; Location Boston, Massachusetts.
| Filed | Fiscal year end | Auditor | PCAOB firm ID | Location | Internal-control attestation |
|---|
| 2026-03-19 | 2025-12-31 | PricewaterhouseCoopers LLP | 238 | Boston, Massachusetts | No |
|---|
| 2025-03-06 | 2024-12-31 | PricewaterhouseCoopers LLP | 238 | Boston, Massachusetts | No |
|---|
| 2024-03-13 | 2023-12-31 | PricewaterhouseCoopers LLP | 238 | Boston, Massachusetts | No |
|---|
| 2023-03-23 | 2022-12-31 | PricewaterhouseCoopers LLP | 238 | Boston, Massachusetts | No |
|---|
| 2022-03-14 | 2021-12-31 | PricewaterhouseCoopers LLP | 238 | Boston, Massachusetts | No |
|---|
| 2021-03-15 | 2020-12-31 | PricewaterhouseCoopers LLP | | Boston, Massachusetts | No |
|---|
| 2020-03-12 | 2019-12-31 | PricewaterhouseCoopers LLP | | Boston, Massachusetts | |
|---|
| 2019-03-13 | 2018-12-31 | PricewaterhouseCoopers LLP | | Boston, Massachusetts | |
|---|
| 2018-03-29 | 2017-12-31 | PricewaterhouseCoopers LLP | | Boston, Massachusetts | |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
|---|
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
|---|
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
|---|